Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Sun Yat-sen University39 enrolled

Overview

The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Carcinoma

Interventions

AnlotinibDRUG

All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * biopsy proved nasopharyngeal carcinoma; * stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy; * 18 years or older; without other malignancy; * proper functioning of the major organs. Exclusion Criteria: * allergic to anlotinib; * female within gestation period or lactation; * patients received drug of other clinical trial within 4 weeks.

Locations (1)

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

disease control rate

Time frame: 30 months

Secondary Outcomes

overall response rate

Time frame: 30 months

progression-free survival

Time frame: 30 months

overall survival

Time frame: 30 months

duration of response

Time frame: 30 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.